10/31/14 GHDX 36.34 Genomic Health $GHDX Hit a 52 week high of 37.74 Closing the day 10/31/14 at 36.34 +0.27 +0.75% With a day low of 35.86 and a total volume of 142,900.
GHDX Recent Posts: http://investorshangout.com/Genomic-Health-GHDX-54227/
GHDX Genomic Health Recent Headline News
Genomic Health to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014
PR Newswire - Tue Oct 28, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 4 at 4:30 p.m. Eastern Time to discuss its third quarter 2014 financial results. The call and webcast will follow the release of the third quarter financial results after market close.
GHDX: 36.34 (+0.27)
Genomic Health Up 10.2% Since SmarTrend Uptrend Call (GHDX)
Comtex SmarTrend(R) - Mon Oct 27, 9:35AM CDT
SmarTrend identified an Uptrend for Genomic Health (NASDAQ:GHDX) on October 10th, 2014 at $30.40. In approximately 2 weeks, Genomic Health has returned 10.22% as of today's recent price of $33.50.
GHDX: 36.34 (+0.27)
Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)
PR Newswire - Wed Oct 22, 4:59PM CDT
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The personalized medicine (global) market is presented as follows:
FMI: 25.88 (-1.11), AMGN: 162.18 (+0.60), GHDX: 36.34 (+0.27)
Should Genomic Health (GHDX) Be in Your Portfolio Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:52PM CDT
On Oct 15, 2014, Zacks Investment Research upgraded Genomic Health Inc. (GHDX) to a Zacks Rank #1 (Strong Buy).
MDVN: 105.70 (+2.96), MYGN: 39.49 (+1.49), HALO: 9.62 (+0.01), GHDX: 36.34 (+0.27)
NewLink Genetics (NLNK) Shows Strength: Stock Up 23.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:46AM CDT
NewLink Genetics (NLNK) was a big mover last session, with shares rising nearly 24% on the day.
HALO: 9.62 (+0.01), NLNK: 32.65 (-1.23), LGND: 55.27 (+0.90), GHDX: 36.34 (+0.27)
Invitae Completes $120 Million Series F Financing
Business Wire - Mon Oct 13, 11:01AM CDT
Invitae Corporation, a genetic information company, today announced the completion of a $120 million Series F financing. Invitae plans to use the proceeds to accelerate the build out of its infrastructure for its genetic information business, as well as to expand its global presence.
JPM: 60.48 (+1.09), GHDX: 36.34 (+0.27)
Integra LifeSciences: A Buy on MicroFrance, Xomed Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 2:00PM CDT
On Oct 7, 2014, Zacks Investment Research upgraded leading medical technology developer Integra LifeSciences Holdings Corporation (IART) to a Zacks Rank #2 (Buy).
MDVN: 105.70 (+2.96), IART: 51.11 (+1.37), MDT: 68.16 (+0.73), GHDX: 36.34 (+0.27)
The Oncotype DX(R) Test and Precision Oncology: New Data Presented at ESMO Further Demonstrate Genomic Health's Successful Approach to Understanding Tumour Biology
Business Wire - Mon Sep 29, 8:00AM CDT
--Further evidence of the practice-changing impact of the Oncotype DX test in breast cancer
GHDX: 36.34 (+0.27)
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
PR Newswire - Mon Sep 29, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence). In meeting these two endpoints, the Oncotype DX prostate cancer test provides both clinically actionable and long-term outcomes information for men with newly diagnosed low- and intermediate-risk prostate cancer. Furthermore, the study demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men.
GHDX: 36.34 (+0.27)
Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
PR Newswire - Fri Sep 26, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ) will be featured as an oral presentation at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 9-13, 2014.
GHDX: 36.34 (+0.27)
Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), ANTH: 1.86 (-0.04), GHDX: 36.34 (+0.27)
New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign with Baseball Hall-of-Famer Joe Torre
PR Newswire - Wed Sep 24, 7:00AM CDT
In partnership with Men's Health Network (MHN), Prostate Health Education Network (PHEN), ZERO - the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one's disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
GHDX: 36.34 (+0.27)
New Developments in the Companion Diagnostics Market 2014
M2 - Wed Sep 24, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zlp33x/companion) has announced the addition of the "Companion Diagnostics Market" report to their offering. There had been a slow market uptake of companion diagnostics because companion tests lacked FDA approval, which prevented pharmaceutical companies from promoting the diagnostic. But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective has made companion diagnostics important to the delivery of care. This report, Companion Diagnostics Markets tracks these new developments and focuses on companion diagnostics in medicine in 2013 and 2014. The report provides product analysis for the five broad areas of medical companion diagnostics and market information: Cancer Cardiovascular and Blood Metabolic Infection Neurological Market Size by Disease Area, 2013 and 2018Companion diagnostics have met with considerable challenges in penetrating the market, but are now rising to the forefront of pharmaceutical development and treatment, increasing the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics and biomarkers provide insight into understanding disease processes and ways that medicines can work to counteract the disease. The majority of competitive participation for companion diagnostics is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market which include large multiproduct companies such as Roche and Abbott and small niche developers such as 20/20 GeneSystems. Key Topics Covered: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION TO THE COMPANION DIAGNOSTICS INDUSTRY THREE: INDUSTRY TRENDS FOUR: COMPANION DIAGNOSTIC PRODUCTS FIVE: MARKET SIZE AND GROWTH SIX: COMPANY PROFILES - 20/20 Genesystems, Inc. - Abbott Laboratories - Affymetrix - Asuragen, Inc. - Beckman Coulter, Inc - Becton, Dickinson - Biocartis S.A. - Biodesix, Inc. - Biomerieux Sa - Bioreference Laboratories, Inc - Biotheranostics, Inc. - Cardiodx, Inc - Celera Alameda - Clarient, Inc - Decode Genetics, Inc. - Diagenic Asa - Genomic Health, Inc. - Genoptix Medical Laboratory - Illumina, Inc. - Johnson & Johnson - Life Technologies Corporation (Part Of Thermo Fisher) - Myriad Genetics, Inc. - Nanostring Technologies, Inc. - Opko Health, Inc. - Provista Dx - Qiagen N.V. - Roche - Siemens Healthcare - Singulex, Inc - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/zlp33x/companion
JNJ: 107.78 (+0.74), ABT: 43.59 (+0.10), MYGN: 39.49 (+1.49), OPK: 8.35 (-0.04), ILMN: 192.58 (-0.84), QGEN: 23.46 (-0.23), GHDX: 36.34 (+0.27)
Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:20PM CDT
Recently, Zacks Investment Research upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).
ALXN: 191.36 (-1.57), ILMN: 192.58 (-0.84), GHDX: 36.34 (+0.27), AFFX: 9.01 (+0.71)
Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer
PR Newswire - Wed Sep 17, 2:13PM CDT
Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is pleased to announce the appointment of Brian Hansen as Chief Commercial Officer (CCO). The addition of Brian to the Company's expanding Executive Leadership Team follows recent key hires from leading global healthcare companies, including Dean Schorno (CFO) and Kathleen Determann (General Counsel) from Genomic Health and Sean Nolan (CTO) from Microsoft's Healthvault.
GHDX: 36.34 (+0.27)
Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:00PM CDT
Currently, Genomic Health (GHDX) is focused on boosting its Oncotype DX portfolio in the international market
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), GHDX: 36.34 (+0.27)
Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics
PR Newswire - Fri Sep 12, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment.
GHDX: 36.34 (+0.27)
Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress
PR Newswire - Tue Sep 09, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville, Md. This new study demonstrates the test's ability to predict a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence) and reconfirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California, San Francisco (UCSF).
GHDX: 36.34 (+0.27)
GHDX Recent Posts: http://investorshangout.com/Genomic-Health-GHDX-54227/
GHDX Genomic Health Recent Headline News
Genomic Health to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014
PR Newswire - Tue Oct 28, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 4 at 4:30 p.m. Eastern Time to discuss its third quarter 2014 financial results. The call and webcast will follow the release of the third quarter financial results after market close.
GHDX: 36.34 (+0.27)
Genomic Health Up 10.2% Since SmarTrend Uptrend Call (GHDX)
Comtex SmarTrend(R) - Mon Oct 27, 9:35AM CDT
SmarTrend identified an Uptrend for Genomic Health (NASDAQ:GHDX) on October 10th, 2014 at $30.40. In approximately 2 weeks, Genomic Health has returned 10.22% as of today's recent price of $33.50.
GHDX: 36.34 (+0.27)
Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)
PR Newswire - Wed Oct 22, 4:59PM CDT
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The personalized medicine (global) market is presented as follows:
FMI: 25.88 (-1.11), AMGN: 162.18 (+0.60), GHDX: 36.34 (+0.27)
Should Genomic Health (GHDX) Be in Your Portfolio Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:52PM CDT
On Oct 15, 2014, Zacks Investment Research upgraded Genomic Health Inc. (GHDX) to a Zacks Rank #1 (Strong Buy).
MDVN: 105.70 (+2.96), MYGN: 39.49 (+1.49), HALO: 9.62 (+0.01), GHDX: 36.34 (+0.27)
NewLink Genetics (NLNK) Shows Strength: Stock Up 23.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:46AM CDT
NewLink Genetics (NLNK) was a big mover last session, with shares rising nearly 24% on the day.
HALO: 9.62 (+0.01), NLNK: 32.65 (-1.23), LGND: 55.27 (+0.90), GHDX: 36.34 (+0.27)
Invitae Completes $120 Million Series F Financing
Business Wire - Mon Oct 13, 11:01AM CDT
Invitae Corporation, a genetic information company, today announced the completion of a $120 million Series F financing. Invitae plans to use the proceeds to accelerate the build out of its infrastructure for its genetic information business, as well as to expand its global presence.
JPM: 60.48 (+1.09), GHDX: 36.34 (+0.27)
Integra LifeSciences: A Buy on MicroFrance, Xomed Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 2:00PM CDT
On Oct 7, 2014, Zacks Investment Research upgraded leading medical technology developer Integra LifeSciences Holdings Corporation (IART) to a Zacks Rank #2 (Buy).
MDVN: 105.70 (+2.96), IART: 51.11 (+1.37), MDT: 68.16 (+0.73), GHDX: 36.34 (+0.27)
The Oncotype DX(R) Test and Precision Oncology: New Data Presented at ESMO Further Demonstrate Genomic Health's Successful Approach to Understanding Tumour Biology
Business Wire - Mon Sep 29, 8:00AM CDT
--Further evidence of the practice-changing impact of the Oncotype DX test in breast cancer
GHDX: 36.34 (+0.27)
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
PR Newswire - Mon Sep 29, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence). In meeting these two endpoints, the Oncotype DX prostate cancer test provides both clinically actionable and long-term outcomes information for men with newly diagnosed low- and intermediate-risk prostate cancer. Furthermore, the study demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men.
GHDX: 36.34 (+0.27)
Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
PR Newswire - Fri Sep 26, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ) will be featured as an oral presentation at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 9-13, 2014.
GHDX: 36.34 (+0.27)
Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), ANTH: 1.86 (-0.04), GHDX: 36.34 (+0.27)
New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign with Baseball Hall-of-Famer Joe Torre
PR Newswire - Wed Sep 24, 7:00AM CDT
In partnership with Men's Health Network (MHN), Prostate Health Education Network (PHEN), ZERO - the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one's disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
GHDX: 36.34 (+0.27)
New Developments in the Companion Diagnostics Market 2014
M2 - Wed Sep 24, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zlp33x/companion) has announced the addition of the "Companion Diagnostics Market" report to their offering. There had been a slow market uptake of companion diagnostics because companion tests lacked FDA approval, which prevented pharmaceutical companies from promoting the diagnostic. But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective has made companion diagnostics important to the delivery of care. This report, Companion Diagnostics Markets tracks these new developments and focuses on companion diagnostics in medicine in 2013 and 2014. The report provides product analysis for the five broad areas of medical companion diagnostics and market information: Cancer Cardiovascular and Blood Metabolic Infection Neurological Market Size by Disease Area, 2013 and 2018Companion diagnostics have met with considerable challenges in penetrating the market, but are now rising to the forefront of pharmaceutical development and treatment, increasing the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics and biomarkers provide insight into understanding disease processes and ways that medicines can work to counteract the disease. The majority of competitive participation for companion diagnostics is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market which include large multiproduct companies such as Roche and Abbott and small niche developers such as 20/20 GeneSystems. Key Topics Covered: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION TO THE COMPANION DIAGNOSTICS INDUSTRY THREE: INDUSTRY TRENDS FOUR: COMPANION DIAGNOSTIC PRODUCTS FIVE: MARKET SIZE AND GROWTH SIX: COMPANY PROFILES - 20/20 Genesystems, Inc. - Abbott Laboratories - Affymetrix - Asuragen, Inc. - Beckman Coulter, Inc - Becton, Dickinson - Biocartis S.A. - Biodesix, Inc. - Biomerieux Sa - Bioreference Laboratories, Inc - Biotheranostics, Inc. - Cardiodx, Inc - Celera Alameda - Clarient, Inc - Decode Genetics, Inc. - Diagenic Asa - Genomic Health, Inc. - Genoptix Medical Laboratory - Illumina, Inc. - Johnson & Johnson - Life Technologies Corporation (Part Of Thermo Fisher) - Myriad Genetics, Inc. - Nanostring Technologies, Inc. - Opko Health, Inc. - Provista Dx - Qiagen N.V. - Roche - Siemens Healthcare - Singulex, Inc - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/zlp33x/companion
JNJ: 107.78 (+0.74), ABT: 43.59 (+0.10), MYGN: 39.49 (+1.49), OPK: 8.35 (-0.04), ILMN: 192.58 (-0.84), QGEN: 23.46 (-0.23), GHDX: 36.34 (+0.27)
Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:20PM CDT
Recently, Zacks Investment Research upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).
ALXN: 191.36 (-1.57), ILMN: 192.58 (-0.84), GHDX: 36.34 (+0.27), AFFX: 9.01 (+0.71)
Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer
PR Newswire - Wed Sep 17, 2:13PM CDT
Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is pleased to announce the appointment of Brian Hansen as Chief Commercial Officer (CCO). The addition of Brian to the Company's expanding Executive Leadership Team follows recent key hires from leading global healthcare companies, including Dean Schorno (CFO) and Kathleen Determann (General Counsel) from Genomic Health and Sean Nolan (CTO) from Microsoft's Healthvault.
GHDX: 36.34 (+0.27)
Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:00PM CDT
Currently, Genomic Health (GHDX) is focused on boosting its Oncotype DX portfolio in the international market
CBPO: 60.25 (+0.60), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22), GHDX: 36.34 (+0.27)
Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics
PR Newswire - Fri Sep 12, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment.
GHDX: 36.34 (+0.27)
Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress
PR Newswire - Tue Sep 09, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville, Md. This new study demonstrates the test's ability to predict a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence) and reconfirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California, San Francisco (UCSF).
GHDX: 36.34 (+0.27)
